NCT04372316Unknown2 期
The Efficacy of Mecobalamin Injection and Tablet Treatment on Mild to Moderate Diabetic Peripheral Neuropathy： a Randomized Controlled Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- changes of inferior whorl length （IWL）from baseline at 8 weeks
研究概览
简要总结
To evaluate the efficacy of mecobalamin injection and tablet in the treatment of small fiber lesions in the early stage of diabetic peripheral neuropathy by corneal confocal microscopy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of type 1 or 2 diabetes for at least 1 year
- •must be consistent with the diagnosis of distal, symmetrical, sensorimotor polyneuropathy
- •according to the clinical judgment of the researchers, the blood glucose has been under the best control. Before screening visit, HbA1c level ≤ 9%. During the course of the study, the blood glucose was adjusted under the guidance of the researchers, and the blood glucose was kept stable as much as possible.
- •Toronto clinical neuropathy score (TCSs) ≤ 5 at screening visit
- •no history of eye injury and laser treatment
- •no history of keratopathy or other intraocular and extraocular diseases
- •no wearing history of corneal contact lens
- •no drugs affecting corneal metabolism
- •no Mecobalamin or lipoic acid in 3 months
- •women of childbearing age (e.g. non-surgical contraception or menopause less than 1 year) must be negative in the gonadotropin pregnancy test (urine) during the screening period, and effective contraceptive measures must be taken during the treatment period and within 1 month after the end of the treatment
- •the participant signs the informed consent, indicating that the subject has been informed of all research related contents
- •participants are willing and able to follow study visit arrangements, treatment plans, laboratory tests and other research procedures
排除标准
- •has been diagnosed as a malignant tumor in the past 2 years.
- •the presence of other neurological disorders that the researchers believe may affect the evaluation of diabetic peripheral neuropathy
- •presence of skin disease in the affected skin area, which, in the judgment of the researchers, may affect the evaluation of diabetic peripheral neuropathy
- •amputations other than finger ends and toes
- •participated in any other studies or post market drugs studies within 30 days prior to screening
- •participants with clinically significant or unstable diseases, such as but not limited to acute cardiovascular disease, cerebrovascular disease, liver, kidney, respiratory system, blood system, immune system, inflammatory or rheumatic disease, uncontrolled infection, symptomatic peripheral vascular disease, untreated endocrine disease, etc
- •have donated blood within 30 days prior to the start of the study treatment (if applicable); or have prepared blood donors during the study or within 30 days after the end of the treatment
- •WBC < 4000 / mm3; neutrophil count < 1500 / mm3; platelet count < 100 × 103 / mm3
- •clinically significant abnormal 12 lead ECG
- •participants received combined transcutaneous electrical nerve stimulation (TENS) or acupuncture
- •previous history of intolerance or allergies to study drugs or drugs with similar chemical structure
- •has a history of alcohol and / or other drug abuse in the past year or is currently under the influence of alcohol or drug abuse
- •the presence of other acute or chronic medical or psychiatric conditions or laboratory abnormalities that, in the judgment of the investigator, may increase the risk associated with participating in the trial or using the study product, or may affect the interpretation of the study results, may make the subject unsuitable for the trial
- •inability and / or unwillingness to understand and / or comply with the program
研究组 & 干预措施
methylcobalamin tablet
Active Comparator
干预措施: methylcobalamin (Drug)
methylcobalamin injection
Active Comparator
干预措施: methylcobalamin (Drug)
结局指标
主要结局
changes of inferior whorl length （IWL）from baseline at 8 weeks
时间窗: 8 weeks
changes of the nerve length of inferior whorl area of each mm2
次要结局
- changes of corneal nerve fiber length（CNFL）from baseline at 8 weeks(8 weeks)
- changes of corneal nerve branch density（CNBD）from baseline at 8 weeks(8 weeks)
- changes of corneal nerve fibre density（CNFD）from baseline at 8 weeks(8 weeks)
- changes of corneal nerve fibre tortuosity （CNFT) from baseline at 8 weeks(8 weeks)
研究者
Fan Dongsheng
Director
Peking University Third Hospital
研究点 (1)
Loading locations...
相似试验
招募中
Unknown
Effectiveness of methylcobalamin and alpha lipoic acid in diabetic neuropathy.Diabetic neuropathy.Autonomic neuropathy in endocrine and metabolic diseasesG99.0IRCT20221122056577N1Abba Darou Teb Co.500
已完成
不适用
Oral/Intramuscular B12 to Treat Cobalamin DeficiencyVitamin B 12 DeficiencyNCT01476007Gerencia de Atención Primaria, Madrid284
进行中（未招募）
3 期
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot SyndromeHand-foot SyndromeNCT05165069Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University234
已完成
4 期
Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant PatientsVasoplegic SyndromeLiver Transplant ComplicationsNCT04054999Mayo Clinic19
Unknown
1 期
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical TrialOral Lichen PlanusNCT04091698Cairo University34